AstraZeneca Breztri met primary endpoints in Phase III trials in asthma Ruchika Sharma4 May 2025 10:30 AM ISTAstraZeneca has announced the Positive high-level results from the Phase III KALOS and LOGOS trials in patients with uncontrolled asthma showed that...
Conduct BE study and clinical trial: CDSCO Panel tells Cipla on Formoterol Fumarate Dihydrate, glycopyrronium inhaler Dr. Divya Colin19 Dec 2023 6:58 PM ISTNew Delhi: Rejecting the proposal for clinical trial and bioequivalence (BE) study waiver presented by drug major Cipla, the Subject Expert Committee...
COPD treatment: CDSCO nod to AstraZeneca India to market triple drug combination inhalation aerosol Ruchika Sharma15 Dec 2023 4:30 PM ISTBangalore: Biopharmaceutical company AstraZeneca India has announced that it has received Central Drugs Standard Control Organisation (CDSCO)...
Provide in-vivo data, global data: CDSCO Panel Tells Glenmark on Pulmonary FDC in Inhalation Suspension Dr. Divya Colin28 Sept 2023 6:00 PM ISTNew Delhi: In reaction to the request for a waiver of bioequivalence (BE) and Phase III clinical trials for the inhalation suspension of the pulmonary...
DoP Directs NPPA to consider Cipla application for retail price fixation of asthma drug combination Farhat Nasim5 Nov 2022 6:00 PM ISTNew Delhi: In a major respite to Cipla Ltd., embroiled in a legal battle for almost three years over the price of an Asthma inhaler drug, the...
